Published in Lab Invest on November 01, 2002
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol (2010) 3.98
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer (2009) 2.60
Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res (2005) 2.43
Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res (2009) 2.23
Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia (2004) 1.92
BRCA1 functions as a breast stem cell regulator. J Med Genet (2004) 1.92
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res (2007) 1.91
Cancer stem cells in breast: current opinion and future challenges. Pathobiology (2008) 1.77
Understanding and treating triple-negative breast cancer. Oncology (Williston Park) (2008) 1.73
BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer (2006) 1.65
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer (2009) 1.57
TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat (2008) 1.44
Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med (2012) 1.43
Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer (2006) 1.29
Demystified...tissue microarray technology. Mol Pathol (2003) 1.28
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst (2010) 1.26
Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann Oncol (2008) 1.12
The TRAIL to targeted therapy of breast cancer. Adv Cancer Res (2009) 1.08
Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer (2007) 1.03
Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry. Br J Cancer (2004) 1.00
Adenomyoepithelial tumours and myoepithelial carcinomas of the breast--a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells. BMC Cancer (2005) 1.00
Triple-Negative Breast Cancer: Clinical and Histological Correlations. Breast Care (Basel) (2011) 1.00
The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. Breast Cancer Res (2003) 0.99
Statistical association of basal cell keratins with metastasis-inducing proteins in a prognostically unfavorable group of sporadic breast cancers. Am J Pathol (2011) 0.95
Immunohistochemical and cytogenetic characterization of acantholytic squamous cell carcinoma of the breast. Virchows Arch (2005) 0.94
Squamous/epidermoid differentiation in normal breast and salivary gland tissues and their corresponding tumors originate from p63/K5/14-positive progenitor cells. Virchows Arch (2014) 0.92
Chromosomal changes in aggressive breast cancers with basal-like features. Cancer Genet Cytogenet (2009) 0.92
Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol (2010) 0.92
Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup. Oncotarget (2013) 0.88
Clinicopathologic features of triple negative breast cancers: an experience from Pakistan. Diagn Pathol (2014) 0.87
Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. Cancer Gene Ther (2014) 0.85
Advances in cancer tissue microarray technology: Towards improved understanding and diagnostics. Anal Chim Acta (2006) 0.85
Novel bright field molecular morphology methods for detection of HER2 gene amplification. J Mol Histol (2004) 0.84
Quantitative assessment of tissue biomarkers and construction of a model to predict outcome in breast cancer using multiple imputation. Cancer Inform (2008) 0.81
Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy. Neoplasia (2012) 0.80
Cytokeratin and protein expression patterns in squamous cell carcinoma of the oral cavity provide evidence for two distinct pathogenetic pathways. Oncol Lett (2016) 0.79
Limitations of tissue microarrays compared with whole tissue sections in survival analysis. Oncol Lett (2010) 0.79
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl) (2016) 0.79
Clinical proteomics of breast cancer. Curr Genomics (2010) 0.79
Invasive Lobular Carcinomas Do Not Express Basal Cytokeratin Markers CK5/6, CK14 and CK17. Breast Cancer (Auckl) (2010) 0.79
N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. Clin Breast Cancer (2015) 0.77
Site-specific gene expression patterns in oral cancer. Head Face Med (2017) 0.77
Treatment Outcomes and Clinicopathologic Characteristics of Triple-Negative Breast Cancer: A Report from Cancer Institute of Iran. Int J Hematol Oncol Stem Cell Res (2017) 0.75
[The significance of "normal tissue" in the development of breast cancer: new concepts of early carcinogenesis]. Pathologe (2006) 0.75
[Early loss of heterozygosity on chromosome arm 16q in flat epithelial atypia of the breast. Detection by microsatellite analyses]. Pathologe (2008) 0.75
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med (2006) 9.85
Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer (2008) 7.99
MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene (2003) 7.90
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med (2009) 5.36
Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA (2004) 4.01
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res (2002) 3.70
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol (2009) 3.63
ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res (2010) 3.54
Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (2003) 3.47
The mzIdentML data standard for mass spectrometry-based proteomics results. Mol Cell Proteomics (2012) 2.82
Web-based virtual microscopy in teaching and standardizing Gleason grading. Hum Pathol (2005) 2.56
Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol (2002) 2.56
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther (2004) 2.47
Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res (2005) 2.39
Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest (2002) 2.33
Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol (2013) 2.19
Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res (2003) 2.15
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol (2011) 2.01
Brief fixation does not affect assessment of hormone receptor expression in invasive breast carcinoma biopsies: paving the road for same-day tissue diagnostics. Am J Surg Pathol (2014) 1.95
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res (2005) 1.93
HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res (2006) 1.93
Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia (2004) 1.92
Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer (2005) 1.91
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res (2007) 1.91
Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol (2003) 1.87
Receptor conversion in distant breast cancer metastases. Breast Cancer Res (2010) 1.85
CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res (2009) 1.81
The application of JPEG2000 in virtual microscopy. J Digit Imaging (2007) 1.76
Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood (2011) 1.73
HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cell Oncol (2009) 1.70
ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol (2004) 1.70
A web-based system for individualised survival estimation in breast cancer. BMJ (2003) 1.70
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther (2007) 1.70
Silver-coated megaendoprostheses in a rabbit model--an analysis of the infection rate and toxicological side effects. Biomaterials (2004) 1.69
Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res (2009) 1.68
Going fully digital: Perspective of a Dutch academic pathology lab. J Pathol Inform (2013) 1.67
Lack of toxicological side-effects in silver-coated megaprostheses in humans. Biomaterials (2007) 1.66
Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res (2003) 1.65
Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res (2011) 1.64
Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol (2002) 1.59
Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J Clin Oncol (2007) 1.58
Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood (2006) 1.58
Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol (2002) 1.56
The sentinel node in cervical cancer: scintigraphy and laparoscopic gamma probe-guided biopsy. Eur J Nucl Med Mol Imaging (2004) 1.56
Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res (2007) 1.54
Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res (2002) 1.54
Safety of avoiding routine use of axillary dissection in early stage breast cancer: a systematic review. Breast Cancer Res Treat (2010) 1.53
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res (2011) 1.53
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res (2002) 1.53
Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell (2005) 1.53
Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res (2008) 1.53
Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif (2003) 1.52
Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma. Oncogene (2003) 1.52
Creation of a fully digital pathology slide archive by high-volume tissue slide scanning. Hum Pathol (2010) 1.52
Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res (2005) 1.51
Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology (2009) 1.51
Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. Genes Chromosomes Cancer (2002) 1.51
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res (2006) 1.51
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer (2010) 1.50
Breast cancer histopathology image analysis: a review. IEEE Trans Biomed Eng (2014) 1.47
implementing data standards: a report on the HUPOPSI workshop September 2009, Toronto, Canada. Proteomics (2010) 1.46
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol (2011) 1.46
Cultures of ovarian surface epithelium from women with and without a hereditary predisposition to develop female adnexal carcinoma. Gynecol Oncol (2004) 1.45
Sentinel node biopsy for nonpalpable breast tumors requires a preoperative diagnosis of invasive breast cancer. Breast J (2003) 1.44
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl) (2006) 1.43
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res (2009) 1.43
Automatic nuclei segmentation in H&E stained breast cancer histopathology images. PLoS One (2013) 1.43
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res (2011) 1.42
Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med (2008) 1.41
Proteomics characterization of mouse kidney peroxisomes by tandem mass spectrometry and protein correlation profiling. Mol Cell Proteomics (2007) 1.41
Patellar articular cartilage lesions: in vitro MR imaging evaluation after placement in gadopentetate dimeglumine solution. Radiology (2004) 1.41
Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers. Endocr Relat Cancer (2012) 1.40
The 3-layered ductal epithelium in gynecomastia. Am J Surg Pathol (2012) 1.40
Linking whole-slide microscope images with DICOM by using JPEG2000 interactive protocol. J Digit Imaging (2009) 1.39
Confocal 3D DNA cytometry: assessment of required coefficient of variation by computer simulation. Cell Oncol (2004) 1.39
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res (2011) 1.39
Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate. Genes Chromosomes Cancer (2008) 1.39
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol (2005) 1.38
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res (2006) 1.38
Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology (2005) 1.37
Association of Wwox with ErbB4 in breast cancer. Cancer Res (2007) 1.37
Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer (2008) 1.37
Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol (2004) 1.37
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett (2010) 1.35
Reporter metabolite analysis of transcriptional profiles of a Staphylococcus aureus strain with normal phenotype and its isogenic hemB mutant displaying the small-colony-variant phenotype. J Bacteriol (2006) 1.34